ss31 freeze-dried powder 99% Purity SS-31 to Treat Heart Failure SS-31 Elamipretide Peptide Elamipretide Lyophilized Peptide Vial 736992-21-5 Jack
92 Inquiries
736992-21-5
Pharmaceutical
99%
HongKong
HUATAI
10vial
2026-11-03
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionElamipretide Synthetic is a single, non-glycosylated polypeptide chain containing 4 amino acids, having a molecular mass of 640 Dalton and a Molecular formula of C32H49N9O5 .Basic Info
-
Product Name:
Elamipretide
Other Name:D-Arginyl-2,6-diMethyl-L-tyrosyl-L-lysyl-L-phenylalaninaMide;Elamipretide;L-Phenylalaninamide, D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-;Elamipretide (TFA salt);SS-31;MTP-131;BENDAVIA;Bendavia);Elamipretide (SS-31;ELAMIPRETIDE, >99%
CAS No.:736992-21-5
Molecular Formula:C32H49N9O5
InChIKeys:SFVLTCAESLKEHH-WKAQUBQDSA-N
Molecular Weight:639.79
Exact Mass:639.38566570
EC Number:205-858-1
UNII:87GWG91S09
DSSTox ID:DTXSID50471988
Color/Form:White to Off-White
Categories:
Characteristics-
Density:
1.34±0.1 g/cm3(Predicted)
PKA:10.10±0.25(Predicted)
Research-
Class:
Mitochondria-targeted tetrapeptide (Szeto-Schiller peptide)
Status:FDA-approved (Forzinity) — Accelerated Approval 2025
Mechanism:A cell-permeable, synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that selectively concentrates in the inner mitochondrial membrane and reversibly binds to cardiolipin, a phospholipid essential for electron transport chain (ETC) function. By stabilizing cardiolipin, SS-31 restores mitochondrial bioenergetics, reduces cytochrome c peroxidase activity, and prevents oxidative damage in cells with impaired mitochondrial function.
Activity note:SS-31 does not act via traditional receptor agonism. It binds cardiolipin with high selectivity in the inner mitochondrial membrane. Functional EC₅₀ values are context-dependent (cell type, stress model). Key electrophysiology studies report mitochondrial membrane potential restoration at nanomolar concentrations.
Source:Szeto HH, et al. AAPS J. 2006;8(2):E277-E283. Birk AV, et al. J Am Soc Nephrol. 2014;25(6):1157-1169.DOI
Clinical Development:FDA:Forzinity (approved 2025-09-19)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
FDA: Forzinity (NDA 215244) — Accelerated Approval 2025; Genetics in Medicine: TAZPOWER Phase 2/3 results (Thompson et al. 2020); Drugs: Elamipretide First Approval (Springer 2025)
Disclaimer:Elamipretide (Forzinity) is FDA-approved under accelerated approval for Barth syndrome. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Location:
1502A1, Building 4, Xinyuanxin Center, No. 3 Huaxin Road, Dongfeng Street, Licheng District, Jinan City, Shandong Province
-
Payment Terms:
TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
1
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
Certifications:
COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA
-
-
Inquiry History92 Inquiries
Country Product Purchase Quantity Date Posted 
United States
SS-31 (Elamipretide MTP-131) CAS 736992-21-5 99% White Powder XO
10 Oct 22, 2023 
Canada
SS-31 (Elamipretide MTP-131) CAS 736992-21-5 99% White Powder XO
1 Sep 28, 2023
United States
SS-31
500 MG Feb 20, 2026 
Philippines
Elamipretide
100 MG Mar 17, 2026
Philippines
Elamipretide / SS-31
5 G Mar 16, 2026 
Kazakstan
SS-31
500 MG May 22, 2026 
Belgium
Elamipretide SS-31
50 MG Jun 18, 2026
United States
Elamipretide
1 MG Jun 18, 2026
United States
Ss-31
30 MG May 20, 2026
United States
SS-31
50 MG May 19, 2026
United States
SS-31
1 KG May 7, 2026
United States
SS-31 (elamipretide)
450 MG May 3, 2026 
Russia
SS-31 Elamipretide
50 G Apr 3, 2026
United States
SS-31
1 G Mar 30, 2026
United States
Elamipretide
10 MT Mar 27, 2026
United States
ss31
1 KG Mar 16, 2026 
Brazil
SS 31 Elamipretide
10 PCS Mar 5, 2026
United States
SS-31
5 G Feb 21, 2026
United States
SS-31
10 MG Feb 20, 2026
United States
Ss-31
100 MG Feb 17, 2026 Post an enquiry for this product